These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 20015104)

  • 1. The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects.
    Hunt RH; Armstrong D; Yaghoobi M; James C
    Aliment Pharmacol Ther; 2010 Mar; 31(6):648-57. PubMed ID: 20015104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers.
    Hunt RH; Armstrong D; James C; Chowdhury SK; Yuan Y; Fiorentini P; Taccoen A; Cohen P
    Am J Gastroenterol; 2005 Sep; 100(9):1949-56. PubMed ID: 16128938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers.
    Galmiche JP; Sacher-Huvelin S; Bruley des Varannes S; Vavasseur F; Taccoen A; Fiorentini P; Homerin M
    Aliment Pharmacol Ther; 2005 Mar; 21(5):575-82. PubMed ID: 15740541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers.
    Galmiche JP; Bruley Des Varannes S; Ducrotté P; Sacher-Huvelin S; Vavasseur F; Taccoen A; Fiorentini P; Homerin M
    Aliment Pharmacol Ther; 2004 Mar; 19(6):655-62. PubMed ID: 15023167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study.
    Miehlke S; Madisch A; Kirsch C; Lindner F; Kuhlisch E; Laass M; Knoth H; Morgner A; Labenz J
    Aliment Pharmacol Ther; 2005 Apr; 21(8):963-7. PubMed ID: 15813831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study.
    Katz PO; Castell DO; Chen Y; Andersson T; Sostek MB
    Aliment Pharmacol Ther; 2004 Aug; 20(4):399-406. PubMed ID: 15298633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
    Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
    Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.
    Li ZS; Zhan XB; Xu GM; Cheng NN; Liao Z
    J Gastroenterol Hepatol; 2007 Jun; 22(6):815-20. PubMed ID: 17565634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.
    Johnson DA; Stacy T; Ryan M; Wootton T; Willis J; Hornbuckle K; Brooks W; Doviak M
    Aliment Pharmacol Ther; 2005 Jul; 22(2):129-34. PubMed ID: 16011671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study.
    Wilder-Smith CH; Röhss K; Bondarov P; Hallerbäck B; Svedberg LE; Ahlbom H
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1099-104. PubMed ID: 15569112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.
    Morelli G; Chen H; Rossiter G; Rege B; Lu Y
    Aliment Pharmacol Ther; 2011 Apr; 33(7):845-54. PubMed ID: 21272047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study.
    Thomson AB; Cohen P; Ficheux H; Fiorentini P; Domagala F; Homerin M; Taccoen A
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1179-87. PubMed ID: 16611279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.
    Goldstein JL; Miner PB; Schlesinger PK; Liu S; Silberg DG
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1189-96. PubMed ID: 16611280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough.
    Hammer J; Schmidt B
    Aliment Pharmacol Ther; 2004 May; 19(10):1105-10. PubMed ID: 15142200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.
    Junghard O; Hassan-Alin M; Hasselgren G
    Eur J Clin Pharmacol; 2002 Oct; 58(7):453-8. PubMed ID: 12389067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of intravenous esomeprazole 40 mg and pantoprazole 40 mg on intragastric pH in healthy subjects. A prospective, open, randomised, two-way cross-over comparative study.
    Piccoli F; Ory G; Hadengue A; Beglinger C; Degen L
    Arzneimittelforschung; 2007; 57(10):654-8. PubMed ID: 18074759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
    Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
    Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: the opportunities and benefits of extended acid suppression.
    Scarpignato C; Pelosini I
    Aliment Pharmacol Ther; 2006 Jun; 23 Suppl 2():23-34. PubMed ID: 16700900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single dose of intravenous esomeprazole decreases gastric secretion in healthy volunteers.
    Nichita C; Abdou AE; Maerten P; Herranz M; Mouret N; Thalmann C; Michetti PF; Dorta G
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1022-9. PubMed ID: 19702644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
    Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
    Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.